anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fat soluble vitamin compositions are prepared by agitating, under reduced pressure, a crude sugar syrup with a fat soluble vitamin containing material.  In examples, shark liver oil and a corn oil solution of irradiated 7-dehydrocholesterol are emulsified in black strap molasses.  In a further example, inverted molasses is used to form an emulsion of cod liver oil. The emulsions are stable, uniform and do not ferment.  They may be added to feeds, milk products and other foods.  Materials containing vitamins A, D, E and K may be used; fish liver oils, sardine oil, herring oil, irradiated ergosterol, chemically activated Liebermann-Burchard sterols and provitamin A are specified.  Emulsifying agents may be employed to assist emulsification.  Before or after emulsification, vitamin C, consistuents of the vitamin B complex, nicotinic acid and the filtrate factor may be added.ALSO:Fat soluble vitamin compositions are prepared by agitating, under reduced pressure, a crude sugar syrup with a fat soluble vitamin containing material in examples, shark liver oil and a corn oil solution of irradiated 7-dehydrocholesterol are emulsified in black strap molasses.  In a further example, inverted molasses is used to form an emulsion of cod liver oil. The emulsions are stable, uniform and do not ferment. They may be added to feeds, milk products and other foods.  Materials containing vitamins A, D, E and K may be used; fish liver oils, sardine oil, herring oil, irradiated ergosterol, chemically activated Liebermann-Burchard sterols and provitamin A are specified. Emulsifying agents may be employed to assist emulsification.  Before or after emulsification, vitamin C, constituents of the vitamin B complex, nicotinic acid, and the filtrate factor may be added.
Many oncology drugs have been found to induce cardiotoxicity in a subset of patients, which significantly limits their clinical use and impedes the benefit of lifesaving anticancer treatments. Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carry donor-specific genetic information and have been proposed for exploring the interindividual difference in oncology drug-induced cardiotoxicity. Herein, we evaluated the inter- and intraindividual variability of iPSC-CM-related assays and presented a proof of concept to prospectively predict doxorubicin (DOX)-induced cardiotoxicity (DIC) using donor-specific iPSC-CMs. Our findings demonstrated that donor-specific iPSC-CMs exhibited greater line-to-line variability than the intraindividual variability in impedance cytotoxicity and transcriptome assays. The variable and dose-dependent cytotoxic responses of iPSC-CMs resembled those observed in clinical practice and largely replicated the reported mechanisms. By categorizing iPSC-CMs into resistant and sensitive cell lines based on their time- and concentration-related phenotypic responses to DOX, we found that the sensitivity of donor-specific iPSC-CMs to DOX may predict in vivo DIC risk. Furthermore, we identified a differentially expressed gene, DND microRNA-mediated repression inhibitor 1 (DND1), between the DOX-resistant and DOX-sensitive iPSC-CMs. Our results support the utilization of donor-specific iPSC-CMs in assessing interindividual differences in DIC. Further studies will encompass a large panel of donor-specific iPSC-CMs to identify potential novel molecular and genetic biomarkers for predicting DOX and other oncology drug-induced cardiotoxicity.
OXYGEN COMPRESSED USP UN 1072 OXYGEN 2 18033 (R 04/05)

WARNING: For emergency use only when administered by properly trained personnel for Oxygen deficiency and resuscitation. For all other medical applications, RX only. Uninterrupted use of high concentrations of Oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Use only with pressure reducing equipment and apparatus designed for Oxygen. Do not attempt to use on patients who have stopped breathing, unless used in conjunction with resuscitative equipment. Produced by Air Liquefaction.

WARNING: HIGH PRESSURE OXIDIZING GAS. VIGOROUSLY ACCELERATES COMBUSTION. Keep oil and grease away. Open valve slowly. Store and use with adequate ventilation.Use only with equipment cleaned for Oxygen service and rated for cylinder pressure. Use a back flow preventive device in piping. Close valve after each use and when empty. Cylinder pressure should not exceed 52 degrees C (125 degrees C). Use in accordance with the Material Safety Data Sheet (MSDS).

CAS: 7782-44-7 DO NOT REMOVE THIS LABEL

MED TECH Since 1961

Medical-Technical Gases, Inc.

20 Hall Street, Medford, MA 02155

TEL. 800 FINE GAS Fax (781) 395-9098

www.medtechgases.com
Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine \<20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
PCT No. PCT/IT92/00057 Sec. 371 Date Jan. 28, 1993 Sec. 102(e) Date Jan. 28, 1993 PCT Filed May 22, 1992 PCT Pub. No. WO92/21359 PCT Pub. Date Dec. 10, 1992The invention relates to active principles having an antineoplastic action, extracted from plants of the family Pittosporacee, and to pharmaceutical preparations based on at least one of the substances or compositions to be found in said extracts. With respect to other known antitumoral drugs, these antineoplastic chemotherapeutic drugs show greater selectivity towards degenerated cells and a lower level of interference with the metabolism of healthy cells. The invention also extends to the process for extraction and separation of the components of the extracts and to their use for the preparation of antineoplastic drugs or drugs for the treatment of other pathologies.
The present study aimed to evaluate the degree of nerve injury on inferior alveolar nerve (IAN) by different implant drills resulting from direct canal intrusion into inferior alveolar canal (IAC). A cadaveric study involving 7 human mandibles was performed to evaluate mechanical injury of canal enclosed IAN resulting from different drills. In group 1, osteotomies were created using different drills with 1 mm of intracanal intrusion, simulating accidental drill intrusion into canal. In group 2, drilling was stopped when the tip has breached into IAC, limited by tactile feedback of operator. The depth and width of nerve defects were assessed using optical coherence tomography. A significant difference in defect depth was found (p < 0.001) in group 1. A sinus lift reamer inflicted the least damage (0.068 ± 0.022 mm). It was also found that the mean defect depth was significantly different when a twist drill was used (p = 0.016). Sinus lift reamer can be used safely for osteotomy preparation in mandible when bone height is limited or when radiographic visualization of canal is poor. Bone corticalization around IAC does not provide adequate protection for IAN in the event of accidental intracanal intrusion.
This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
This study is a randomized control trial and will include all patients who are agreeable and deemed appropriate for alloplastic breast reconstruction involving the use of an ADM with two stage tissue expander (TE) reconstruction. The ADMs used will be determined by random assignment to one of four available products being utilized within the study: AlloDerm, AlloMax, DermACELL and FlexHD. Each ADM product will comprise of an individual treatment arm. Participants undergoing bilateral reconstruction will have the same ADM used in each side. The four treatment arms will be compared to assess their impact on our primary outcome: proportion of clinically significant post-operative seroma requiring intervention. Analysis will be performed per surgeon to prevent post-operative outcomes from being confounded by the principle operator. The trial will initially be conducted as an internal pilot study. The study will initially target a study population of 40 patients for recruitment as a means to assess the feasibility of the study. In doing this, the pilot study will be able to establish the necessary protocol and administrative infrastructure that is needed to complete the trial in its entirety. This create a sample population for initial outcomes.
NEW MATERIAL: A polyvalent metal salt of a sulfonated deriv. of benzylidenecamphor represented by formula I [wherein M n+  is a polyvalent metal cation (n is 2, 3, or 4); and one of X 1  and X 2  is H and the other is a group of formula II or III].  
     USE: An ultraviolet screening agent.  
     PROCESS: A polyvalent metal salt of formula IV (wherein Z is an inorg. or org. anion; and m is 1 or 2) and a hydroxide, optionally in the form of a soln. or an aq. dispersion, are added to an aq. soln. of a benzylidenecamphor deriv. of formula V (wherein A is H, an alkali metal, etc.; and one of X' 1  and X' 2  is H and the other is a group of formula II or III) to give a compd. of formula I. The polyvalent metal salt is added under stirring. The compd. of formula I in an amt. of 0.25-3 wt.% (based on the total wt. of the compsn.) is incorporated into a cosmetic compsn. 
     COPYRIGHT: (C)1990,JPO
The invention relates to the technical field of medicine, and particularly relates to a suspension that covers a solid medicine with oil (hereinafter referred to as solid-in-oil) and a preparing method thereof, and the suspension is used for improving oral bioavailability of risedronate sodium. The solid-in-oil suspension comprises the medicine, a surfactant and an outer oil phase. The outer oil phase is mixed decanoyl and octanoyl glycerides. The adding weight of the outer oil phase is 70-96.5% of the weight of the solid-in-oil suspension. The adding weight of the surfactant is 1.75-22.5% of the weight of the solid-in-oil suspension. The adding weight of the medicine is 0.5-7.5% of the weight of the solid-in-oil suspension. The dispersity of the water soluble medicine in the oil substrate is improved by preparing a composite of the medicine and the surfactant. A proper oil substrate can be selected according to targeting parts without influences on the dispersity of the medicine in the oil.
BACKGROUND: Previous studies have found that psychological interventions have a positive effect on improving physical and psychological problems in colorectal cancer survivors. However, there is still a lack of high-quality evidence reviews that summarize and compare the impact of different psychological interventions. The aim of this study was to synthesize existing psychological interventions and use network meta-analysis to explore whether psychological interventions improve anxiety, depression, fatigue and quality of life in colorectal cancer (CRC) survivors.
METHODS: We will extract relevant randomized controlled trials of psychological interventions for CRC survivors from eight electronic databases, including PubMed, Embase, The Cochrane Library, Web of Science, CINAHL, PsycInFO, CNKI, and Wanfang database. Two reviewers will independently screen the literature and extract data. The risk of bias of the included studies will be assessed using the RoB2: Revised Cochrane Risk of Bias Tool. We will then conduct paired meta-analyses and network meta-analyses of the extracted data, using a frequency-based framework and random effects models.
DISCUSSION: To the best of our knowledge, this study is the first proposed qualitative and quantitative integration of existing evidence using systematic evaluation and network meta-analysis. This study will inform health policy makers, healthcare providers' clinical intervention choices and guideline revisions, and will help to reduce depression and anxiety in CRC survivors, reduce fatigue, improve quality of life.
After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
LMNA-related muscular dystrophy is a major disease phenotype causing mortality and morbidity in laminopathies, but its pathogenesis is still unclear. To explore the molecular pathogenesis, a knock-in mouse harbouring the Lmna-W520R mutation was modelled. Morphological and motor functional analyses showed that homozygous mutant mice revealed severe muscular atrophy, profound motor dysfunction, and shortened lifespan, while heterozygotes showed a variant arrangement of muscle bundles and mildly reduced motor capacity. Mechanistically, the FOXO1/GADD45A pathway involving muscle atrophy processes was found to be altered in vitro and in vivo assays. The expression levels of FOXO1 and its downstream regulatory molecule GADD45A significantly increased in atrophic muscle tissue. The elevated expression of FOXO1 was associated with decreased H3K27me3 in its gene promotor region. Overexpression of GADD45A induced apoptosis and cell cycle arrest of myoblasts in vitro, and it could be partially restored by the FOXO1 inhibitor AS1842856, which also slowed the muscle atrophy process with improved motor function and prolonged survival time of homozygous mutant mice in vivo. Notably, the inhibitor also partly rescued the apoptosis and cell cycle arrest of hiPSC-derived myoblasts harbouring the LMNA-W520R mutation. Together, these data suggest that the activation of the FOXO1/GADD45A pathway contributes to the pathogenesis of LMNA-related muscle atrophy, and it might serve as a potential therapeutic target for laminopathies.
Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
N-methyl-D-aspartate receptor-dependent excitotoxicity is one of the most important mechanisms underlying stroke injury and the resulting neuronal death. In the present study, in order to reduce post-stroke brain injury and improve behavioral performance, a new molecule named IC87201, which acts as an inhibitor of PSD95/nNOS interaction in the intracellular signaling pathway of NMDA receptors, was administered. Using the middle cerebral artery occlusion (MCAO) technique, 24 adult male rats were subjected to one hour of cerebral ischemia. Animals were randomly divided into sham, MCAO, MCAO + DXM, and MCAO + IC87201 groups, and in the last two groups, intraperitoneal injection of dextromethorphan hydrobromide monohydrate (DXM), as an NMDA antagonist, and IC87201 was performed after ischemia. Neurobehavioral scores were evaluated for seven days, and on the last two days, the rats' memory performance was appraised using the passive avoidance test. On seventh day, the brain tissue was properly prepared for stereological analysis. Stereological studies of the hippocampus CA1 and CA3 regions revealed that changes in the total and infarcted volumes, total number of neurons, non-neurons, and dead neurons are the consequences of cerebral ischemia. Also, following cerebral ischemia, neurobehavioral and memory function impairments which were assessed by modified neurological severity scores (mNSS) and passive avoidance test, were observed. The aforementioned impairments were recovered after administration of IC87201 significantly and more potently than DXM. Based on our findings, IC87201 successfully attenuated post-ischemia damages. Therefore, this molecule can be considered as a new therapeutic approach in future research.
INTRODUCTION: Osteonecrosis of the femoral head (ONFH) is a refractory disease requiring joint replacement in young patients. Regenerative therapies have been developed.
AREAS COVERED: This study surveyed clinical trials on regenerative medicine for ONFH. We extracted clinical trials on non-traumatic ONFH from the websites of five publicly available major registries (EuropeanUnion Clinical Trials Register ([EU-CTR],ClinicalTrials.gov, Chinese ClinicalTrial Registry [ChiCTR], University Hospital Medical InformationNetwork - Clinical Trial Registry [UMIN-CTR] and Australian New Zealand Clinical Trials Registry [ANZCTR]).The trials were classified into six categories based on purpose: surgical treatment, non-drug conservative treatment, conservative drug treatment, therapeutic strategy, diagnosis and pathogenesis, and regenerative therapy.) We extracted 169 clinical trials on ONFH. Of these, 37 were on regenerative medicine, including 29 on cell therapy. Surgical treatment was the most common treatment, followed by regenerative therapy.There were 9 clinical trials registered in the EU-CTR, with 5 on regenerative medicine; 79 trials registered on ClinicalTrials.gov, with 24 on regenerativemedicine; 54 trials registered in the ChiCTR, with 6 on regenerative medicine.
EXPERT OPINION: The focus of the joint-preserving surgery has shifted to regenerative therapy based on using cell therapy in early-stage ONFH. The global standardisation of regenerative therapy is still ongoing.
Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
Upon encountering pathogens, the immune system typically responds by initiating an acute and self-limiting reaction, with symptoms subsiding after the pathogen has been cleared. However, long-term post-infectious clinical symptoms can manifest months or even years after the initial infection. 'Trained immunity', the functional reprogramming of innate immune cells through epigenetic and metabolic rewiring, has been proposed as a key concept for understanding these long-term effects. Although trained immunity can result in enhanced protection against reinfection with heterologous pathogens, it can also contribute to detrimental outcomes. Persisting and excessive inflammation can cause tissue damage and aggravate immune-mediated conditions and cardiovascular complications. On the other hand, suppression of immune cell effector functions by long-lasting epigenetic changes can result in post-infectious immune paralysis. Distinct stimuli can evoke different trained immunity programs, potentially resulting in different consequences for the host. In this review, we provide an overview of both the adaptive and maladaptive consequences of infectious diseases. We discuss how long-term immune dysregulation in patients can be addressed by tailoring host-directed interventions and identify areas of scientific and therapeutic potential to advance further.
The present invention relates to a method for improved diagnosis of cervical lesions based on detection of gene products encoded by the INK4a gene locus. According to the present invention an improvement in diagnosis may be achieved by assessing the presence or absence or the level of overexpression of at least two different gene products encoded by the INK4a gene locus. In another aspect the present invention relates to peptides derived from cell cycle regulatory proteins, the expression of which is altered in association with tumors in individuals. These peptides according to the present invention may be used for detection and therapy of tumors. For detection purposes the peptides may for example be used to detect antibodies directed against said peptides. In therapeutic respect the peptides may be used for immunotherapy or vaccination approaches. In therapeutic and diagnostic respect the peptides may be used in combination with one or more peptides derived from tumor associated proteins.
The invention relates to a synthetic single-stranded oligonucleotide of 10-40 nucleotides in length, comprising a transcriptional regulatory sequence (TRS) or part thereof from a virus of the order Nidovirales. In embodiments the oligonucleotide is not a siRNA. A further aspect of the invention relates to a pharmaceutical composition comprising a synthetic single-stranded oligonucleotide of the invention, wherein said composition comprises a pharmaceutically acceptable carrier enabling intracellular delivery. A further aspect of the invention relates to a synthetic single-stranded oligonucleotide of the invention for use in the prevention and/or treatment of a Nidovirales infection, wherein the oligonucleotide is of 10-40 nt in length, and comprises a transcriptional regulatory sequence (TRS) or part thereof from a virus of the order Nidovirales. The virus of the order Nidovirales is preferably a coronavirus. The oligonucleotide of the invention is intended for use in the treatment of a coronavirus infection.
This study will recruit a number of participants who are going to sail for mariana trench from Shenzhen, China. Characteristics of the participants will be described by a series of index of stool, urine, skin microbiota and tongue coating. All the biospecimen will be collected before and during the voyage. Stool at the 2nd, the 4th and the 12th week after the voyage and blood sample at the baseline will also be collected. Participants' mood states, health-related quality of life, fatigue score and sleep quality will be investigated with questionnaires throughout the 1-month period. Participants are asked to record diseases and symptoms, if any, when sailing. All the data will be used to analyse how microbiota change and be involved in human health during a voyage.